European studies on breast lymphatic mapping.

Area of Science:

• Oncology
• Surgical Oncology
• Breast Cancer Research

Background:

• Sentinel lymph node (SLN) biopsy is a minimally invasive alternative for nodal staging in breast cancer.
• Current evidence relies on case-control trials, showing high predictive accuracy (false-negative rate <5%) for SLN biopsy.
• SLN biopsy can identify patients benefiting from axillary dissection and spare node-negative patients from morbidity.

Purpose of the Study:

• To review European multicenter randomized trials evaluating sentinel lymph node dissection in breast cancer.
• To assess the oncologic safety and reduced postoperative morbidity of SLN biopsy.
• To determine if SLN biopsy can be accepted as the standard of care.

Main Methods:

• Review of European multicenter randomized trials.
• Trials include ALMANAC, AMAROS-EORTC, KiSS, Milan, Fransenod, and IBCSG 23-01.
• Focus on SLN dissection as a surrogate for axillary dissection and procedural aspects.

Main Results:

• Data from case-control trials indicate SLN biopsy is highly predictive of axillary node status.
• A false-negative rate of less than 5% has been reported.
• Randomized trials are required to validate oncologic safety and reduced morbidity.

Conclusions:

• Randomized trials are essential to establish sentinel lymph node biopsy as the standard of care for breast cancer nodal staging.
• Further data are needed to confirm the oncologic safety and reduced morbidity associated with SLN biopsy.
• European multicenter trials are actively investigating the pros and cons of SLN dissection.